More on ACRS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $5.40 |
|
|||
| Open | $5.41 | ||||
| 52 Wk High | $33.88 | ||||
| 52 Wk Low | $14.12 | ||||
| Day High | $5.54 | ||||
| Day Low | $5.36 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,687,999 | ||||
- Aclaris Therapeutis (ACRS) Reiterated at Overweight by Cantor Fitzgerald
- Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
- Canaccord Starts Aclaris Therapeutis (ACRS) at Buy
- Piper Sandler on Aclaris Therapeutis (ACRS): 'Efficacy Differentiation Could Drive Share Re-Rate'
- Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
- Form 8-K Aclaris Therapeutics, For: Aug 06
- Form S-3ASR Aclaris Therapeutics,
- Form 10-Q Aclaris Therapeutics, For: Jun 30
- FDA grants fast track status to Aclaris drug for lichen planus
- Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP)
Entities mentioned with ACRS
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
